Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
NASDAQ:ALLR

Allarity Therapeutics 11/14/2025 Earnings Report

Allarity Therapeutics logo
$1.48 +0.08 (+5.71%)
Closing price 04:00 PM Eastern
Extended Trading
$1.48 0.00 (0.00%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Allarity Therapeutics EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Allarity Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Allarity Therapeutics Announcement Details

Quarter
Date
11/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Allarity Therapeutics' next earnings date is estimated for Friday, May 8, 2026, based on past reporting schedules.

Conference Call Resources

Allarity Therapeutics Earnings Headlines

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
May 5 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287619/0/en/allarity-therapeutics-advances-stenoparib-toward-pivotal-development-with-phase-3-manufacturing-campaign.html
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 15.7% in April
May 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30753697
The Death of the Nasdaq?
The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software stocks two months before they crashed this year. Now, he's warning that one AI lab's breakthrough could CRASH the Nasdaq while igniting a $500 trillion wealth transfer. He's found a little-known $40 "pre-IPO backdoor" into the private startup behind this economic sea change.tc pixel
May 6 at 1:00 AM  |  Chaikin Analytics (Ad)
Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Friday
May 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30750645
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3281537/0/en/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office.html
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall ...
April 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/allarity-therapeutics-presents-two-aacr-2026-posters-highlighting-stenoparib-s-potential-in-colorectal-cancer-as-well-as-new-predictive-data-linking-drp-and-overall-survival-in-ovarian-cancer-1036042478
See More Allarity Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Allarity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allarity Therapeutics and other key companies, straight to your email.

About Allarity Therapeutics

Allarity Therapeutics (NASDAQ:ALLR) A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials. These programs explore combinations of targeted therapy and standard chemotherapy in colorectal, ovarian and breast cancers. Allarity’s diagnostic platform supports these efforts by employing gene expression signatures to match treatments with tumor biology, offering a more personalized approach than conventional “one‐size‐fits‐all” regimens.

Founded in 2015 as OncoBay, the company rebranded to Allarity Therapeutics in 2020 to reflect its expanded precision medicine strategy. Headquartered in Copenhagen, Denmark, Allarity maintains a U.S. presence in Cambridge, Massachusetts, to facilitate clinical collaborations and regulatory interactions. Under the leadership of CEO Christian M. Vedelsdal and an experienced executive team, the company has built partnerships with research institutions and contract organizations to advance its clinical programs.

Allarity serves global markets by enrolling patients across North America and Europe in its ongoing trials. The company’s outward focus on combining diagnostics with therapeutics aligns with an evolving industry trend toward more targeted and data‐driven drug development, positioning Allarity to address significant unmet needs in oncology with a precision‐guided approach.

View Allarity Therapeutics Profile
Earnings Tools